-

AHF: Global HIV Response Demands Broader Lenacapavir Access

LOS ANGELES--(BUSINESS WIRE)--While AIDS Healthcare Foundation (AHF) welcomed news of Gilead’s expansion of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers, key HIV-affected countries excluded from the deal—particularly those in Latin America and others—must also have affordable access to this breakthrough treatment, irrespective of their World Bank income classification.

“This license excludes 2 million people living with HIV in Latin America — notably in Brazil, Mexico, Argentina, Colombia, and Peru. It excludes them because Gilead sees the Latin American market as a place where it can profit off the backs of sick people. Generic access to lenacapavir is a step in the right direction, especially for improving treatment adherence, but a drug with this much promise to save countless lives must be affordable to all nations that need it,” said AHF President Michael Weinstein.

“And while generic manufacturers in India, Pakistan, Egypt, and the U.S. have been granted licenses,” added Weinstein, “South Africa has a robust pharmaceutical sector and should have been included in the deal to address its own enormous HIV burden and help support the response across the rest of the continent at a reduced cost.”

Further concerns remain around pricing transparency as Gilead and the licensees are yet to clarify how lenacapavir will be priced in the included countries. AHF strongly believes lenacapavir must be made accessible to all countries at an affordable price that reflects the realities on the ground and is in line with the global HIV/AIDS targets.

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 2 million people in 48 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Senior Director of Media Relations, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

AIDS Healthcare Foundation


Release Versions

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323.308.1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Senior Director of Media Relations, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

More News From AIDS Healthcare Foundation

Florida Health Department Retreats on HIV/AIDS Drug Cuts

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--In a notice published earlier today, the Florida Department of Health (DOH) retreated on its decision to make cuts to the State's AIDS drug program, which provides life-saving medications and health insurance support to over 30,000 Floridians living with HIV/AIDS. Alleging that an undocumented $120 million budget shortfall necessitated the cuts, the cuts to the program, originally scheduled to be enacted on March 1st, would adversely impact the life-savin...

AHF: Drain the Apexus Swamp

WASHINGTON--(BUSINESS WIRE)--AHF: Drain the Apexus Swamp...

AHF Receives Expedited Florida Hearing Opposing ADAP Reductions

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--AHF Receives Expedited FL Hearing Opposing ADAP Reductions...
Back to Newsroom